HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,453,510 | +6.3% | 38,050 | +0.4% | 0.00% | 0.0% |
| Q2 2023 | $1,367,414 | -13.8% | 37,910 | -8.8% | 0.00% | -25.0% |
| Q1 2023 | $1,586,795 | -32.9% | 41,550 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $2,364,195 | +18.9% | 41,550 | -17.4% | 0.01% | +20.0% |
| Q3 2022 | $1,989,000 | -11.5% | 50,310 | -1.5% | 0.01% | 0.0% |
| Q2 2022 | $2,248,000 | +5.2% | 51,100 | -4.6% | 0.01% | +25.0% |
| Q1 2022 | $2,136,000 | -0.8% | 53,560 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $2,154,000 | -1.4% | 53,560 | -0.2% | 0.00% | 0.0% |
| Q3 2021 | $2,184,000 | -10.4% | 53,694 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $2,438,000 | +8.9% | 53,694 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $2,239,000 | -30.9% | 53,694 | -29.2% | 0.00% | -42.9% |
| Q4 2020 | $3,240,000 | +34.4% | 75,854 | -17.3% | 0.01% | +40.0% |
| Q3 2020 | $2,410,000 | -2.0% | 91,704 | 0.0% | 0.01% | -16.7% |
| Q2 2020 | $2,459,000 | +49.0% | 91,704 | 0.0% | 0.01% | +20.0% |
| Q1 2020 | $1,650,000 | +1.5% | 91,704 | 0.0% | 0.01% | +25.0% |
| Q4 2019 | $1,626,000 | +14.3% | 91,704 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,422,000 | -9.7% | 91,704 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,575,000 | +6.7% | 91,704 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $1,476,000 | +10.0% | 91,704 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $1,342,000 | -19.4% | 91,704 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,666,000 | +7.7% | 91,704 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,547,000 | -13.8% | 91,704 | +0.2% | 0.00% | -20.0% |
| Q1 2018 | $1,794,000 | -3.3% | 91,554 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $1,855,000 | +16.7% | 91,554 | 0.0% | 0.01% | +25.0% |
| Q3 2017 | $1,590,000 | +35.4% | 91,554 | 0.0% | 0.00% | +33.3% |
| Q2 2017 | $1,174,000 | -1.1% | 91,554 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,187,000 | +31.2% | 91,554 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $905,000 | -18.2% | 91,554 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,106,000 | +40.0% | 91,554 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $790,000 | -9.1% | 91,554 | -0.2% | 0.00% | 0.0% |
| Q1 2016 | $869,000 | -45.3% | 91,726 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $1,590,000 | +29.1% | 91,726 | 0.0% | 0.01% | +20.0% |
| Q3 2015 | $1,232,000 | -40.5% | 91,726 | 0.0% | 0.01% | -28.6% |
| Q2 2015 | $2,071,000 | +64.8% | 91,726 | +4.2% | 0.01% | +75.0% |
| Q1 2015 | $1,257,000 | +44.6% | 88,054 | -2.2% | 0.00% | +33.3% |
| Q4 2014 | $869,000 | +6.0% | 90,079 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $820,000 | -7.9% | 90,079 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $890,000 | -18.6% | 90,079 | +4.6% | 0.00% | -25.0% |
| Q1 2014 | $1,094,000 | -15.3% | 86,127 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $1,291,000 | +35.8% | 86,127 | 0.0% | 0.00% | +33.3% |
| Q3 2013 | $951,000 | +39.0% | 86,127 | 0.0% | 0.00% | +50.0% |
| Q2 2013 | $684,000 | – | 86,127 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |